Sera Prognostics, Inc. (SERA)
2.03
0.00 (0.00%)
USD |
NASDAQ |
Oct 20, 16:00
2.09
+0.06
(+2.96%)
Pre-Market: 20:00
Sera Prognostics Research and Development Expense (TTM) : 12.27M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.27M |
| March 31, 2026 | 12.07M |
| December 31, 2025 | 12.35M |
| September 30, 2025 | 12.29M |
| June 30, 2025 | 12.52M |
| March 31, 2025 | 13.45M |
| December 31, 2024 | 13.78M |
| September 30, 2024 | 14.51M |
| June 30, 2024 | 14.40M |
| March 31, 2024 | 13.70M |
| December 31, 2023 | 13.97M |
| September 30, 2023 | 13.77M |
| Date | Value |
|---|---|
| June 30, 2023 | 14.76M |
| March 31, 2023 | 14.66M |
| December 31, 2022 | 14.24M |
| September 30, 2022 | 13.83M |
| June 30, 2022 | 12.38M |
| March 31, 2022 | 11.94M |
| December 31, 2021 | 11.02M |
| September 30, 2021 | 10.04M |
| June 30, 2021 | 9.20M |
| March 31, 2021 | 8.128M |
| December 31, 2020 | 7.782M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Myriad Genetics, Inc. | 105.80M |
| BioRestorative Therapies, Inc. | 9.374M |
| CareDx, Inc. | 79.87M |
| Natera, Inc. | 787.38M |
| Exagen, Inc. | 6.466M |